Follicum recruits a Chief Business Officer

September 4, 2017

Follicum recruits a Chief Business Officer

Follicum AB (“Follicum”) today announces the recruitment of Gunnar Gårdemyr as its Chief Business Officer (“CBO”).

Gårdemyr has 35 years of international experience which includes leadership, business development, global marketing and commercial strategy from the pharmaceutical and biotechnology industries. His most recent position was as CEO of Targovax AS in Norway. Prior to this he has been an adviser for Acino Pharma AG in Switzerland, senior vice president of corporate development/M&A, and global business development at Nycomed in Denmark and senior vice president of global marketing at Takeda in Switzerland. Gunnar Gårdemyr began his career within Astra, followed by Ferring, Tigran Technologies and Retinalyze. He holds a degree in business economics from the University of Lund. Gårdemyr will commence his position from tomorrow, the 5th of September, 2017.

CEO Jan Alenfall comments
We are pleased to welcome Gunnar Gårdemyr to Follicum. Our capacity to attract a leader with Gunnar’s broad international experience reflects the potential of the company. His experience and network will accelerate the company’s continued development, especially within the areas of partnerships and strategy.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: 046 – 19 21 97
E-mail: info@follicum.com

Mikael Theander, Communications & PR
Telephone: 0764-263542
E-mail: info@follicum.com

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 4th September, 2017.

About Follicum AB
Follicum was founded in 2011 by two researchers in Lund, Anna Hultgårdh and Pontus Dunér, based on research around a human protein, osteopontin. Among other things, this protein is considered to be involved in the growth of bone tissue. Follicum has isolated a part of this protein and partially modified its amino acid sequence, which generated Follicum’s drug candidate FOL-005. In early studies, FOL-005 showed an ability to both stimulate and inhibit hair growth. During 2016/2017, the company conducted its first clinical phase I/IIa study. Follicum is based in Lund and was listed on AktieTorget in 2014.

Open Press release